Pro Medicus shares rocketed 161% in 2024: Is it still a buy?

Let's see whether analysts think this high-flying stock can keep rising.

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Limited (ASX: PME) shares were a great place to invest last year.

The health imaging technology company was one of the best performers on the ASX 200 index in 2024.

Over the period, the ASX 200 tech stock continued to hit record high after record high and ended with a remarkable annual gain of 161%.

This means that if you had invested $10,000 at the end of the previous year, you would have seen your investment grow to $26,100.

But how did we get here? What drove its shares higher? Let's find out.

Why did Pro Medicus shares smash the market?

Investors were scrambling to buy the company's shares last year after it delivered more explosive sales and earnings growth and announced huge new contract wins.

In respect to the former, Pro Medicus continued its long run of growth, reporting a 29.3% lift in revenue to $161.5 million for FY 2024. This was driven by increased revenue from North America (up 34.4%) and Australia up (5.9%), which offset a 6.7% decline in European revenue. The latter reflects one-off revenue from a sale to a German hospital in the prior corresponding period.

And with Pro Medicus' underlying EBIT margin expanding to 69.5% (from 67.2%), its earnings grew at an even quicker rate. Underlying profit before tax lifted 35.3% to $116.5 million and net profit grew 36.5% to $82.8 million in FY 2024.

Big contract wins

As mentioned above, some major contract wins were announced during the 12 months which gave Pro Medicus shares a further boost.

The largest of those contracts was a whopping 10-year deal signed with Trinity Health that is worth $330 million.

Commenting on the deal, Pro Medicus CEO Sam Hupert, said:

Trinity Health is our largest customer to date and the first with a national footprint. Our initiative with Trinity Health is noteworthy for its scope and scale which will see the Visage 7 platform used by over 650 Radiologists and thousands of clinicians who will benefit from the proven differentiation of Visage 7.

And with its pipeline remaining strong and spanning all market segments, there may be plenty more to come in 2025.

Is it too late to buy?

Goldman Sachs doesn't believe it is too late to buy Pro Medicus shares. It currently has a buy rating and $278.00 price target on them. The broker commented:

PME is not cheap, trading on 114x FY26E EV/EBITDA, but we highlight its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. Additionally, with a focus on the US regulatory outlook, we believe MedTech is increasingly being evaluated as a safe haven within healthcare as it is generally more insulated from impending policy volatility. Our 12m TP is +26% to A$278. Stay Buy.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

Man looking at digital holograms of graphs, charts, and data.
Technology Shares

2 amazing ASX tech shares I wish I'd bought last year

These tech companies are among the world’s best companies.

Read more »

A man in a business suit and tie places three wooden blocks with the numbers 1, 2, and 3 on them on top of each other.
Broker Notes

3 reasons to buy this booming ASX All Ords tech stock today

A leading broker forecasts more gains to come from this surging ASX All Ords tech stock.

Read more »

Man ponders a receipt as he looks at his laptop.
Technology Shares

Brokers rerate 3 leading ASX 200 tech stocks

Experts reveal their ratings on the ASX 200 tech sector's three biggest companies.

Read more »

Hologram of a man next to a human robot, symbolising artificial intelligence.
AI Stocks

Why Macquarie forecasts a big rebound for these 2 quality ASX All Ords tech stocks

Macquarie expects a big rebound is coming for these AI linked, ASX All Ords tech stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Technology Shares

Is it too late to buy DroneShield shares?

This high-flying stock is up 90% since this time last month. Where next? Let's find out.

Read more »

A frustrated male investor frowns with his hands and arms open asking why the share price has dropped today.
Technology Shares

Why this high-flying ASX 200 tech stock just got downgraded

Let's see which stock has been hit with a downgrade today.

Read more »

Delighted adult man, working on a company slogan, on his laptop.
Technology Shares

Up 10% in a day, why this ASX tech share is exciting investors

It’s been a good start to the week for this company’s shareholders.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Technology Shares

Which ASX 200 tech stock is jumping 8% to record high?

This high-flying stock had another strong quarter.

Read more »